Asembia 2023 Summit to Provide Insight Into Health Equity, IRA, and More


Several presentations at the 2023 Asembia Specialty Pharmacy Summit, held in Las Vegas, Nevada, from April 30 through May 4, will cover how to address health equity concerns in specialty pharmacy care, the expansion of the biosimilars market, and the impact of the Inflation Reduction Act (IRA) on the US health care system.

Asembia’s 2023 Specialty Pharmacy Summit is scheduled to be held from April 30 through May 4 in Las Vegas, Nevada, featuring a keynote speech from Seema Verma, MPH, former CMS administrator.

Sessions and panels will dive into several hot topics in health care, including addressing health equity concerns within practices, updates on the specialty pharmacy pipeline, and how 2023 is expected to change the biosimilar industry.

The first day and a half of sessions will be dominated by continuing education courses, covering topics such as optimizing treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma, the role specialty pharmacists can play in introducing disease-specific therapy for geographic atrophy secondary to age-related macular degeneration, and improving care for pediatric patients with atopic dermatitis.

Policy discussions will cover the Inflation Reduction Act (IRA) and its impact on patient financial struggles, as well as best practices for implementing the IRA’s drug pricing policies for manufacturers, plans, and pharmacy stakeholders.

On the health equity side, presentations will explore what strategies are and aren’t working in the health care space to address diversity, equity, and inclusion, and how including women in health care and policy discussions can help correct the historical underrepresentation of women and advance health equity.

Updates on the specialty pharmacy pipeline and the rare disease treatment space will be provided, along with discussions on how practices can utilize prescription digital therapeutics and artificial intelligence to improve care.

In biosimilars, attendees will learn about the expansion of the biosimilar industry and the current status of adoption rates, market share, and savings. Panelists will also provide insight into how payers have responded to biosimilars and how the industry will usher in over 12 specialty pharmacy biosimilars over the next couple years.

During a session entitled “How to Knit an FMV Ugly Holiday Sweater for Enhanced Specialty Pharmacy Services,” attendees will gain a better understanding of fair market value (FMV), how its calculated, and how it can be effectively managed. The panel promised to be helpful for anyone providing or purchasing services in specialty pharmacy.

The conference will take place at the Wynn & Encore hotel, with over 6000 industry attendees expected at the in-person event.

Keep an eye on our Asembia conference page for live coverage from Las Vegas, starting May 2.

Related Videos
Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi
RAvin Ratan, MD, MEd, MD Anderson
Melissa B. Jones, MD, staff nurse psychiatrist, Michael E. DeBakey VA Medical Center; assistant professor of psychiatry, Baylor College of Medicine
Ali Khawar
Monica Kraft, MD, ATSF.
Michael Arzt, MD.
Julie Linton, MD, FAAP.
Jan Hedner, MD, PhD.
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Related Content
CH LogoCenter for Biosimilars Logo